

**Innovative Medicines Initiative** 

# Patient involvement in the PROactive project

## Dr. W.I. de Boer, Netherlands Asthma Foundation





Patient participation: why? (1)



**Chronically diseased patients:** 

- Have their disease knowledge
- Have experience with their disease treatment and living




**Patient organizations** 





combined patients' disease knowledge and experiences





Patient participation: why? (2)



Patient participation as a means for:

- more relevance of the research
- better quality of the research
- better results and chances for societal implementation

Patient participation as a goal for:

- more patient empowerment
- higher democratic decision making level in research, its policy, budgetting



(Abma & Broerse, Health Expectations 13, 2010:160; Hanley et al, INVOLVE 2003; Telford et al, Br J Clin Gov 7, 2002:92; etc.)




IMI Stakeholder Forum – 30 May 2012 - Brussels

## Level of patient participation (based on: Arnstein's and Wilcox' ladder)



- patient is co-producer or leader
  - equal partner in decision making
  - consultation/advisor
  - information provider
- subject in research



## All levels should be achieved



(Arnstein. J Am Instit Planners 1969, 35: 216-224; Wilcox. A to Z of Participation. Joseph Rowntree Foundation, 1999)










### Development of tools to measure physical activity status

#### Aim:

Development of <u>Patient Reported Outcomes that measure</u> aspects of physical activity relevant to patients and are sensitive to changes due to treatment.






# **Participation in:**

- ✓ patient advisory board (driving force)
- ✓ Internal Ethics Board (advisory)
- ✓ Steering committee (advisory & co-decision)
- Meetings with project partners (based on equality)



(boards have European-wide representation)









IMI Stakeholder Forum – 30 May 2012 - Brussels

# **Impression by patients**





excellent opportunity to involve patients and


to listen to their needs and wishes



Involvement

- Travel for meeting
- Language barrier
- Expectations
- Visibility
- Knowledge

(data from meeting together with patients from IMI U-BIOPRED study Sept. 2011)





# Patient participation: profits for other projects/initiatives



- Why and how patient participation in research is useful
- Tools for evaluation, monitoring and collaboration
- Raising broader awareness on patient participation
- Opinion of patients in development of PROs also taken to regulatory agencies
- Broad collaboration between patient/- organisations, science, health care and (pharma) companies:
  - can be effectuated and
  - worthwhile in delivering societally relevant results





# Why an IMI project?



- Patient participation: not yet broadly recognised as a positive contribution and need to science
- IMI JI identified reasons and defined policy for inclusion patient participation in research
- Collaboration on a European level with multidisciplinary interaction sharing knowledge
- Despite not having patient participation in all IMI projects: PROactive, U-BIOPRED and EUPATI prove to be good examples







Dr. W.I. (Pim) de Boer Contact E: <u>deboer.pim@hetnet.nl</u>

In collaboration with:

- Thierry Troosters (KU Leuven, B)
- Janneke Elberse (VU University, Amsterdam, NL)
- Truus Teunissen (NAF; and VUMC, Amsterdam, NL)

Damijan Erzen (Boehringer Ingelheim, D)



